Shionogi's Q2 R&D spending rises to 35.6 billion yen from 27.5 billion
Shionogi reported second-quarter R&D expenses of 35.6 billion yen, up from 27.5 billion yen a year earlier, according to Dow Jones Newswires data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Japanese drugmaker Shionogi spent 35.6 billion yen on research and development in the second quarter. A year earlier, the figure stood at 27.5 billion yen.
The figures were published by Dow Jones Newswires. The source material gives no breakdown of the spending.
why it matters
A notable increase in R&D outlays means the company is putting more money into drug development, which can weigh on near-term profit. Investors often watch such spending to judge a pharma company's priorities and the outlook for its pipeline.
market impact
Shionogi and Japanese pharma: higher R&D costs may weigh on near-term profit
tags
instruments
sources
- Shionogi 2Q R&D Expenses Y35.6B Vs Y27.5B a Year Earlier — Dow Jones Newswires, 29 October 2026 at 04:09 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗